Organogenesis Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORGO research report →
Range $2 – $3
Price Chart
About the company
Organogenesis Holdings Inc. is a U. S.
- CEO
- Gary S. Gillheeney
- IPO
- 2017
- Employees
- 854
- HQ
- Canton, MA, US
Get TickerSpark's AI analysis on ORGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $100.16M
- P/E
- -0.64
- PEG
- -0.00
- P/S
- 0.28
- P/B
- 0.82
- EV/EBITDA
- -2.57
- Div Yield
- 0.00%
- Gross Margin
- 61.98%
- Op Margin
- -22.84%
- Net Margin
- -40.23%
- ROE
- -46.25%
- ROIC
- -24.29%
Latest fiscal year · YoY change
- Revenue
- $563.03M+16.8%
- Gross Profit
- $425.51M+16.2%
- Op Income
- $55.87M
- Net Income
- $37.03M+4201.0%
- EPS
- $0.16+2353.5%
- OCF Growth
- -172.6%
- FCF Growth
- -685.7%
- 52W High
- $5.91
- 52W Low
- $0.73
- 50D MA
- $1.12
- 200D MA
- $2.16
- Beta
- 1.27
- RSI (14)
- 36
- Avg Volume
- 846.67K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Organogenesis reported a sharp year-over-year revenue decline in Q3, but management said the skin substitute market has bottomed and expects sequential improvement, with positive adjusted EBITDA in Q4 at the high end of guidance.· November 5, 2026
- Q3 net product revenue was $45.5 million, down 70% year over year, but up 6% sequentially from Q2.
- Gross profit fell to $23.6 million, or 52% of revenue, versus 76% last year, reflecting the weaker mix and market disruption.
- Management said the skin substitute market has “clearly bottomed out,” with improving market share, but recovery is still being slowed by excess low-cost inventory and customer confusion.
- Full-year 2026 revenue guidance was narrowed to $179 million-$200 million, and management still expects positive adjusted EBITDA in Q4 at the high end of the range.
- Amnuvx’s FDA review has been extended after a pre-license inspection found 18 remediation items; management now expects remediation to finish by September 30, 2027.
Net product revenue was $45.5 million, down 70% year over year. Advanced Wound Care revenue was $38.2 million, down 73%, and Surgical & Sports Medicine revenue was $7.3 million, down 19%. Gross profit was $23.6 million, or 52% of net product revenue, compared with 76% last year. Operating loss was $29.5 million versus operating income of $20.7 million last year; GAAP net loss was $29.6 million versus net income of $21.6 million last year, and adjusted EBITDA loss was $22.4 million versus adjusted EBITDA of $30.1 million last year. For 2026, management now expects total net revenue of $179 million-$200 million, implying a 65%-68% decline year over year; this includes Advanced Wound Care sales of $151 million-$171 million, Surgical & Sports Medicine sales of $26 million-$27 million, and $1.9 million of grant income. They also expect more than a 60% reduction in adjusted EBITDA loss in the second half versus the first half at the low end, and more than 80% reduction at the high end, including positive adjusted EBITDA in Q4 at the high end.
Gary Gillheeney said the company is benefiting from a reshaped market where weaker competitors have exited, and he framed Organogenesis as a “biologic company” with the broadest evidence-based portfolio. He emphasized that the company is gaining share across Apligraf, PuraPly AM, Affinity, and NuShield, and that evidence and clinical data will be increasingly important as reimbursement policies evolve. His tone was cautious on near-term recovery but notably optimistic on the long-term position of the business.
Dave Francisco emphasized the large year-over-year revenue drop but pointed to improving sequential trends, with total revenue up 6% quarter over quarter. He highlighted major cost actions, including a $55.2 million decline in operating expenses year over year and approximately $45 million of total expense reduction expected in 2026, of which about $32 million is related to restructuring. He said the company had $26.9 million in cash equivalents and restricted cash at quarter-end, no debt, and expects existing cash plus product cash flow to fund operations and capex for at least the next 12 months. On Amnuvx-related facility remediation, Gary said the total cost is about $8 million, with about $4 million incremental.
Analysts focused on when the skin substitute market might truly recover, whether the company had seen the bottom, and how much low-cost inventory from exiting competitors is still depressing the market. Management said it believes the market has bottomed, expects the excess inventory to flush through by the end of the year, and thinks clarity should improve by Q1 as price and volume normalize. On Amnuvx, management said the FDA remediation work at Norwood is expected to be completed by September 30, 2027, with about $8 million in total remediation spend, roughly half of which was described as pulled-forward investments that would have been done anyway.
The company is still gaining share in a disrupted market, with management saying growth is broad-based across several products and supported by evidence and clinical data. Cost reductions are material, cash is sufficient for at least 12 months, and management still expects positive adjusted EBITDA in Q4 at the high end of guidance.
Revenue is still far below last year, with a 70% year-over-year drop in Q3 and a full-year outlook that still implies a 65%-68% decline. The recovery remains uncertain because excess inventory, reimbursement confusion, and delayed clinician adoption are still affecting the category, while Amnuvx has suffered a timing delay after FDA inspection findings extended the PDUFA timeline.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 47.9%
- Shares Outstanding
- 129.80M
- Float Shares
- 62.19M
of shares held by institutions
137 13F filers
Buy/sell ratio 0.88. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 11.78M | ▲ 63.22K |
| Soleus Capital Management, L.P. | 10.14M | ▲ 55.00K |
| Blackrock, Inc. | 7.74M | ▲ 492.37K |
| Vanguard Group Inc | 4.96M | ▼ 77.14K |
| Aqr Capital Management LLC | 3.01M | ▲ 2.13M |
| Vanguard Capital Management LLC | 2.95M | ▲ 40.16K |
| D. E. Shaw & Co., Inc. | 2.89M | ▲ 590.34K |
| Dimensional Fund Advisors LP | 2.45M | ▼ 601.29K |
| Acadian Asset Management LLC | 1.97M | ▲ 429.51K |
| Geode Capital Management, LLC | 1.84M | ▼ 99.15K |
| Deutsche Bank AG\ | 1.70M | ▼ 7.29K |
| Vanguard Portfolio Management LLC | 1.52M | ▼ 90.75K |
Held by 136 ETFs
Biggest fund positions in ORGO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 10, 25 | Grow Brian | other | 958 |
| Jan 10, 25 | Grow Brian | other | 958 |
| Mar 9, 26 | Leibowitz Arthur S | buy | 5,000 |
| Mar 9, 26 | Driscoll Michael Joseph | buy | 10,000 |
| Mar 1, 26 | Cavorsi Robert | other | 700 |
| Feb 18, 26 | Montecalvo Antonio S. | other | 11,330 |
| Feb 18, 26 | Montecalvo Antonio S. | other | 3,778 |
| Feb 18, 26 | Gillheeney Gary S. | other | 188,856 |
| Feb 18, 26 | Gillheeney Gary S. | other | 91,311 |
| Feb 18, 26 | Grow Brian | other | 48,818 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ORGO coverage
Recent articles, reports, and earnings notes.

Should You Buy the BioStem Technologies IPO? Here's the Setup
BioStem Technologies, Inc. (NASDAQ: BSEM) is expected to list on 2026-08-07, but the price range has not been disclosed. The company is coming to market through an expected Nasdaq uplisting rather than a traditional IPO prospectus. The bull case is a high-margin wound-care platform; the bear case is heavy customer concentration and a 2025 revenue drop.

Conexeu Sciences Inc. IPO: What to Know Before It Lists
Conexeu Sciences Inc. (NASDAQ: CNXU) is expected to list on 2026-05-21, with the price range not yet disclosed. The setup is a preclinical regenerative medicine story with no FDA-cleared product yet, so shareholders should watch for pricing, dilution, and how the market values the pipeline risk.
Want a deeper read on ORGO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Organogenesis Holdings Inc. (ORGO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Organogenesis: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 6
Organogenesis Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
globenewswire.com · Oct 12
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 12
These beaten-down stocks could bounce back in January, if history is any guide
marketwatch.com · Sep 21
BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGO
defenseworld.net · Sep 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.